ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トリメタジジン

Trimetazidine

HCID 21109
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
5011-34-7
標準SMILES
COc1ccc(CN2CCNCC2)c(OC)c1OC
InChIKey
UHWVSEOVJBQKBE-UHFFFAOYSA-N
分子式
C14H22N2O3
平均分子量
266.34 g/mol
単同位体質量
266.16304257

概要

1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.

名称と識別子

優先名称
Trimetazidine
IUPAC
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
現地名
トリメタジジン
英語名
Trimetazidine
分子式
C14H22N2O3
分子量
266.34

名称と別名

TRIMETAZIDINE5011-34-71-[(2,3,4-trimethoxyphenyl)methyl]piperazineTrimetazidinaTrimetazidinumDilatanN9A0A0R9S8Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-DTXSID2048531Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-1-((2,3,4-trimethoxyphenyl)methyl)piperazineVastarel MR
名称をさらに表示
トリメタジジン1-(2,3,4-トリメトキシベンジル)ピペラジン1-[(2,3,4-トリメトキシフェニル)メチル]ピペラジンTRIMETAZIDINE HCLVasorelVasartelAKOS B006602TIMTEC-BB SBB007020ART-CHEM-BB B006602ART-CHEM-BB B014361Trimetazidine USP/EP/BP
RefChem:191732DTXCID9027998C01EB15225-690-21-(2,3,4-Trimethoxybenzyl)piperazineMFCD008682631-(2,3,4-Trimethoxy-benzyl)-piperazinePreductal

データベース識別子

CAS
5011-34-7
PubChem CID
21109
DTXSID
DTXSID2048531
ChEMBL
CHEMBL203266
ChEBI
CHEBI:94789
UNII
N9A0A0R9S8
EC Number
225-690-2
Nikkaji
J8.797A

物性

構造計算による物性

XLogP
1
極性表面積
43 Ų
水素結合供与体数
1
水素結合受容体数
5
回転可能結合数
5
重原子数
19
形式電荷
0
複雑度
259

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Listed in ZINC15

LogP1.04
Dissociation ConstantspKa1= 4.45 ± 0.02 and pKa2= 9.14 ± 0.02

物理化学的性質

沸点
2 · bp2 200-205°
比重(密度)
1.092 · 1.092±0.06 g/cm3(Predicted)
蒸気圧
0.003 Pa · 0.003Pa at 25℃
貯蔵温度
Hygroscopic, Refrigerator, Under inert atmosphere
溶解性
クロロフロム(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
9.07 · 9.07±0.10(Predicted)
色
無色~淡黄色 ジェル~
安定性
吸湿性
LogP
1.143 at · 1.143 at 25℃ and pH6
CAS データベース
5011 · 5011-34-7(CAS DataBase Reference)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H226 (66.7%): Flammable liquid and vapor [Warning Flammable liquids]

P210, P233, P240, P241, P242, P243, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P303+P361+P353, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: Trimetazidine (EC: 225-690-2)
Hazard Classes and CategoriesFlam. Liq. 3 (66.7%)

毒性情報

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimetazidine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

hazard_code
Xi
hazard_class
IRRITANT

化学と産業

薬理情報

ATC Code · 3 件

C01EB15

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingTrimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.
Pharmacodynamics · 1 件

Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.

Mechanism of Action · 1 件

During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid. The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility. This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma. When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury. The mechanism of action of trimetazidine is not fully understood. Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium. The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility. However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine's target, and that this mechanism may be incorrect.

Biological Half-LifeIn young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.
Metabolism/Metabolites · 1 件

Trimetazidine can be oxidized at the piperazine ring to form trimetazidine ketopiperazine. Trimetazidine can also be N-formylated, N-acetylated, or N-methylated at the piperazine ring to form N-formyltrimetazidine, N-acetyltrimetazidine, and N-methyltrimetazidine respectively. Alternatively, trimetazidine can be demethylated at the 2, 3, or 4 position of the 2,3,4-trimethoxybenzyl moiety to form 2-desmethyltrimetazidine, 3-desmethyltrimetazidine, or 4-desmethyltrimetazidine. The desmethyltrimetazidine metabolites can undergo sulfate conjugation or glucuronidation prior to elimination.

関連反応

14 件
反応記録を作成
HRID 22261 の反応式
HRID 22261反応物として
HRID 37177 の反応式
HRID 37177反応物として
HRID 37178 の反応式
HRID 37178反応物として
HRID 298576 の反応式
HRID 298576反応物として
HRID 307602 の反応式
HRID 307602反応物として
HRID 568735 の反応式
HRID 568735反応物として
HRID 694702 の反応式
HRID 694702反応物として
HRID 945736 の反応式
HRID 945736反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
MeSH Pharmacological ClassificationDrugs used to cause dilation of the blood vessels.
Absorption, Distribution and Excretion · 4 件

In elderly patients, a 35 mg oral modified release tablet reaches a mean Cmax of 115 µg/L, with a Tmax of 2.0-5.0 hours, and a mean AUC0-12 of 1104 h\*µg/L. In young, healthy patients, the same dose reaches a mean Cmax of 91.2 µg/L, with a Tmax of 2.0-6.0 hours, and an AUC0-12h 720 h\*µg/L.

Trimetazidine is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.

The volume of distribution of trimetazidine is 4.8 L/kg.

Trimetazidine clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.

応用分野

用途冠血管拡張薬冠血管を拡張する

上流・下流製品情報

上流原料

炭酸ナトリウム1-ホルミルピペラジン2,3,4-トリメトキシベンジルクロリドトリメタジジンN-カルボン酸エチルエステル1-Chloromethyl-2,3,4-trimethoxybenzene2,3,4-トリメトキシベンズアルデヒド1-(tert-ブトキシカルボニル)ピペラジン

下流製品

ロメリジン塩酸塩